Compare MasterCard Inc (MA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Medpace Holdings Inc — how do they compare? MasterCard Inc trades at $538.35 (market cap $483.71B), while Medpace Holdings Inc trades at $530.22 (market cap $15.08B). The key difference: MasterCard Inc is far larger — about 32.1× Medpace Holdings Inc's market cap, and MasterCard Inc pays a 0.64% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MA | MEDP | |
|---|---|---|
Market Cap | $483.71B | $15.08B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $598.96 | $620.59 |
52-Week Low | $471.55 | $308.88 |
Enterprise Value | $494.45B | $14.55B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $537.76, down 1.07% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates exceptional profitability with 45.88% net margins and consistent earnings beats, including Q1 2026 EPS of $4.60 beating expectations of $4.41. Revenue growth remains robust, climbing from $22.2B in 2022 to $32.8B in 2025, while institutional buying activity continues to support the stock.
Mastercard presents a compelling growth story with strong fundamentals and analyst support, though elevated valuation metrics and competitive payment innovations warrant monitoring. The consensus price target of $634.27 suggests 18% upside potential, supported by 79% analyst buy ratings. Key risks include payment industry disruption from stablecoins and AI-driven payment systems.
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
